By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics said today that it has agreed to buy personalized diagnostics company RedPath Integrated Pathology in a deal that could be worth a total of $32 million.

Paris-based ExonHit plans to buy RedPath, a developer of DNA-based cancer tests, for $12.5 million upfront, another $10 million in stock, and for sales milestone payments that could total another $9.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.